3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Early Stage Triple Negative ER Low Breast Cancer
1
Interventions
Magnetic Resonance Spectroscopy
287
Specimen Handling
285
pembrolizumab
258
Cyclophosphamide
237
Radiotherapy
233
Nivolumab
187
Cisplatin
174
Biopsy
170
Carboplatin
155
Radiosurgery
142
fludarabine
131
Blood Specimen Collection
130
Surveys and Questionnaires
120
Gemcitabine
120
Paclitaxel
115
venetoclax
114
Standard of Care
112
Dexamethasone
105
Bevacizumab
98
Radiation
97
Rituximab
92
Oxaliplatin
89
Cytarabine
88
Capecitabine
88
Drug Therapy
86
Ipilimumab
85
Doxorubicin
83
durvalumab
81
atezolizumab
76
fludarabine phosphate
73
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Interleukin 1 Receptor Antagonist Protein
×
90 days
×
Clear all
NCT06710197
2026-03-05
OZM-034
University Health Network, Toronto
Phase 2
Withdrawn